F10 and atrial fibrillation: The Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial, a three-group, randomized, double-masked, double-dummy trial comparing two-dose regimens of edoxaban with warfarin.